Metagenomi Q2 EPS $(0.29) Beats $(0.65) Estimate
Portfolio Pulse from Benzinga Newsdesk
Metagenomi (NASDAQ:MGX) reported a Q2 EPS loss of $(0.29), significantly beating the analyst consensus estimate of $(0.65) and showing a 92.41% improvement over the same period last year.
August 14, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Metagenomi reported a Q2 EPS loss of $(0.29), which is significantly better than the analyst estimate of $(0.65) and shows a substantial improvement from the previous year's loss of $(3.82) per share.
The significant beat on EPS estimates and the substantial year-over-year improvement in losses are likely to positively impact Metagenomi's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100